Haemonetics HAE Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Net revenues by Business | ||||||
| Blood Center | $56.41M+0.7% | $56.56M-19.6% | $56.45M-17.6% | $51.84M-21.7% | $56.01M— | |
| Hospital | $159.65M+8.0% | $143.5M-0.3% | $145.5M+5.1% | $139.66M+4.2% | $147.86M— | |
| Plasma | $130.29M+2.8% | $138.91M+3.5% | $125.36M-9.5% | $129.9M-4.4% | $126.74M— | |
| Operating Income by Business | ||||||
| Blood Center | $11.24M+13.3% | $13.03M-9.1% | $14.83M-6.2% | $10.89M-14.8% | $9.92M— | |
| Hospital | $29.57M+35.7% | $25.92M-5.3% | $29.86M+28.3% | $18.38M+11.2% | $21.79M— | |
| Plasma | $43.69M-13.7% | $50.23M+5.2% | $42.59M-4.1% | $48.29M+15.7% | $50.63M— | |
| Costs incurred, net of reversals by Business | ||||||
| Blood Center | -$22K-104% | $822K+20.0% | -$338K-114% | -$1.02M-188% | $501K-52.7% | |
| Hospital | $95K-63.5% | $115K-85.1% | $540K+62.2% | $576K+93.9% | $260K-76.7% | |
| Plasma | $0— | -$43K-156% | -$77K-153% | $568K+802% | —— | |
| SG&A by Business | ||||||
| Blood Center | $13.48M-9.6% | $13.47M-5.9% | $13.5M-11.2% | $13.68M-12.3% | $14.91M-11.4% | |
| Hospital | $67.03M+7.0% | $59.94M+1.4% | $57.97M-1.4% | $62.32M+1.9% | $62.63M+19.5% | |
| Plasma | $27.27M+11.3% | $27.1M+15.1% | $24.76M-2.0% | $26.2M+4.2% | $24.49M-10.7% | |
| Cost of goods sold by Business | ||||||
| Blood Center | $30.67M+3.0% | $29.1M-27.7% | $26.95M-25.8% | $25.95M-28.3% | $29.79M-28.0% | |
| Hospital | $54.59M+0.3% | $49.1M+0.8% | $49.32M+3.4% | $50.22M+3.1% | $54.42M+30.2% | |
| Plasma | $54.39M+14.9% | $56.81M-3.2% | $53.02M-19.3% | $49.92M-23.6% | $47.33M-28.3% | |
| Total long-lived assets by Business | ||||||
| Blood Center | $39.68M-1.6% | $41.33M— | $39.46M— | $38.41M— | $40.34M-25.7% | |
| Hospital | $59.72M+10.8% | $48.06M— | $55.3M— | $54.71M— | $53.88M+17.2% | |
| Plasma | $206.37M+8.7% | $207.84M— | $204.26M— | $193.74M— | $189.83M-10.1% | |
| R&D by Business | ||||||
| Blood Center | $1.03M-26.3% | $966K-34.6% | $1.18M-3.0% | $1.32M-21.7% | $1.4M-29.8% | |
| Hospital | $8.46M-6.2% | $8.54M-2.6% | $8.35M-3.3% | $8.74M+14.7% | $9.01M+32.4% | |
| Plasma | $4.94M+15.4% | $4.77M+10.9% | $4.99M+58.7% | $5.5M+47.8% | $4.28M+24.1% | |
| Restructuring related costs by Business | ||||||
| Blood Center | $0-100% | -$1K-103% | $0-100% | $0-100% | $34K-71.7% | |
| Hospital | $0-100% | $0+100% | $0— | $0-100% | $103K+930% | |
| Plasma | $0-100% | $0-100% | $0-100% | $9K-94.9% | $18K-97.6% | |
| D&A by Business | ||||||
| Blood Center | $1.79M-28.9% | $1.79M-28.9% | $1.79M-28.9% | $1.79M-28.9% | $2.52M-24.7% | |
| Hospital | $14.3M-0.1% | $14.3M-0.1% | $14.3M-0.1% | $14.3M-0.1% | $14.31M+50.2% | |
| Plasma | $11.84M-1.9% | $11.84M-1.9% | $11.84M-1.9% | $11.84M-1.9% | $12.07M+5.6% | |
| Currency translation by Business | ||||||
| Blood Center | -$89K— | —— | —— | $240K+200% | —— | |
| Plasma | $0— | $0— | $0— | $0— | $0— | |
| Goodwill by Business | ||||||
| Blood Center | $26.89M-0.3% | $26.98M-6.1% | $27.09M-19.3% | $27.21M-18.2% | $26.97M-19.5% | |
| Hospital | $600.44M+9.5% | $550.81M+0.6% | $549.97M-0.6% | $551.05M0.0% | $548.26M+9.1% | |
| Plasma | $29.04M0.0% | $29.04M0.0% | $29.04M0.0% | $29.04M0.0% | $29.04M0.0% | |
| Total net revenues by Product | ||||||
| Plasma | $130.29M+2.8% | $138.91M+3.5% | $125.36M-9.5% | $129.9M-4.4% | $126.74M-9.1% | |
| Net revenues by Geography | ||||||
| Europe | $52.9M+25.1% | $48.28M+9.3% | $42.97M+2.3% | $40.88M-13.4% | $42.28M+5.6% | |
| Japan | $18.4M+14.3% | $18.14M+12.1% | $18.01M+9.7% | $13.65M-0.4% | $16.11M+10.9% | |
| Other | $3.11M+12.3% | $1.81M-63.3% | $3.68M-30.1% | $2.81M-57.1% | $2.77M-16.6% | |
| Rest of Asia | $19.97M-5.6% | $23.03M-10.0% | $22.57M-12.4% | $21.65M+9.4% | $21.16M-21.3% | |
| United States | $251.97M+1.5% | $247.71M-3.9% | $240.09M-6.2% | $242.4M-2.6% | $248.29M+2.4% | |
| Total long-lived assets by Geography | ||||||
| Europe | $32.08M+60.2% | $30.77M— | $25.29M— | $24.18M— | $20.02M+30.8% | |
| Japan | $916K-26.7% | $1.05M— | $1.2M— | $1.23M— | $1.25M-21.7% | |
| Other | $17.23M+2.2% | $18.03M— | $17.93M— | $17.8M— | $16.86M-20.7% | |
| Rest of Asia | $30.83M+7.4% | $31.54M— | $30.94M— | $29.83M— | $28.71M+7.4% | |
| United States | $224.7M+3.4% | $215.85M— | $223.66M— | $213.83M— | $217.21M-11.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Haemonetics break its business down?
- Haemonetics (HAE) reports net revenues by business across 3 parts — Blood Center, Hospital and Plasma. Each is extracted from the segment footnotes and tracked over time.
- Where does Haemonetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Haemonetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.